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Abstract. While in general, studies on foreign acquisitions by emerging multinationals (EMNEs) have 
predicted these acquisitions to be driven by both market-seeking and strategic resource-seeking motiva-
tions, more concrete analyses on this topic are limited. This paper contributes to the existing literature 
by analyzing the overseas acquisition activities of EMNEs from Indian pharmaceutical sector. Using 
the general framework of technological change in emerging economies, Indian pharmaceutical firms 
are identified to have delicate weakness in their product development capabilities to face intensifying 
competition in the globalized policy regime. It makes sense for these firms to internationalize through 
acquisitions of foreign assets that help them not only access new markets but also new products and 
technologies to overcome their limited product development competencies. The empirical findings high-
light the role of host market size, intensity of patenting, skill and liberal FDI policy regime as the key 
determinants of the geographical distributions of Indian pharmaceutical acquisitions. This implies 
that EMNEs from Indian pharmaceutical industry are using acquisition as a mixed strategy of acces-
sing markets as well as strategic assets/resources.
Key words: Emerging multinationals, Indian pharmaceutical MNEs, overseas mergers and acquisiti-
ons, technological change, FDI location choice.
1. introduction
The emergence of strategic asset-seeking activities undertaken by firms from emerging 
economies has been a recent phenomenon and relatively a less explored area in the 
literature of international production. The number and size of overseas acquisitions 
by emerging multinationals (EMNEs) are now multiplying rapidly. The mergers and 
acquisitions (M&A) purchase of emerging economies stood at $120 billion in 2008, 
accounting for almost 18 per cent of global M&A purchase as against its share of just 
4 per cent in 1998 (UNCATD, 2009). This development possesses implications for 
* Email: pradhanjayaprakash@gmail.com. The author is thankful to three anonymous referees of the 
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theoretical models of FDI that hitherto concentrated on strategic asset-seeking FDI 
from developed countries.
Although EMNEs’ foreign acquisitions are driven by a set of multiple firm-
specific objectives, the motivation of accumulating new technological, marketing and 
skill capabilities has become a key feature of the current M&A wave from emerging 
economies like India, China, Korea and Taiwan (Dunning et al., 1996; Deng, 2004; 
UNCTAD, 2006; Wang & Boateng, 2007; Pradhan, 2008a; Gammeltoft et al., 2010). 
The concentration of emerging firms’ acquisitions in advanced industrialized countries 
that are relatively more endowed with the knowledge assets lend further support to 
their strategic asset-seeking motivations. It is also argued that strategic M&As from 
developing countries representing lagging technical locations are for a technological 
upgrade or catching up whereas those from developed countries representing leading 
technical centers are for technological diversification (Cantwell & Janne, 1999). 
In the above backdrop, the present study analyzes the recent overseas acquisition 
activities of EMNEs from Indian pharmaceutical sector. Using the general framework of 
technological change in developing countries, this paper put forth the perspective that 
recent overseas acquisitions of EMNEs can partly be related to their initial low product 
development capabilities at the time of starting of the economic openness programme 
by the home economy in the early 1990s. With the opening up of the economy to 
global competition during the last two decades and adoption of product patent regime 
in 2005, Indian pharmaceutical firms were forced to change the scale and focus of their 
in-house R&D to increasingly redress their limited product development capabilities. 
Several studies have confirmed such a tactical shift in the competitive strategy of Indian 
pharmaceutical companies (Mueller, 2007; Kale & Little, 2007; Chaturvedi et al., 2007). 
This paper argues that overseas acquisitions by EMNEs from Indian pharmaceutical 
industry are also pursued for broadening the product development capabilities, besides 
other firm-specific objectives.
Section 2 presents the framework of technological change in emerging economies 
for analyzing the development of Indian pharmaceutical sector and identifying the 
technological gaps that characterizes the long-run growth of the Indian pharmaceutical 
firms. It emphasizes on the nature of technological change that took place under the 
protected policy regime and spells out how innovation activities of Indian pharmaceutical 
firms remain restricted to just process developments. Besides considering the 
technological and other benefits that overseas acquisitions might have on acquiring 
Indian pharmaceutical firms, Section 3 focuses on trends and geographical pattern of 
foreign acquisitions by Indian pharmaceutical companies. Section 4 formulates and 
estimates a relevant locational model by incorporating different possible motivations 
of Indian pharmaceutical MNEs behind their foreign acquisition activities. Section 5 
summarizes the key findings and provides concluding remarks. 
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2. technological change and technology gaps in emerging economies
As per the past literature, technology developments in developing countries during the 
1970s to the 1980s were more of adaptive innovation associated with imports of foreign 
technologies (Nelson, 1987; Teitel, 1987). These involve adaptation of imported 
technology to the local environment, demand and factor conditions and incremental 
improvements thereon. Some developing countries like South Korea, Taiwan, China, 
Malaysia, Indonesia, Thailand and Israel succeeded in using the acquired technology to 
further build up their indigenous capabilities across a wide range of sectors. National 
firms in these countries leveraged from business-financed R&D characterized by an 
evolving mix of imitative and innovative technological activities (Bell & Pavitt, 1995). 
Imitation and reverse engineering provided in the weak patent regime also contributed 
to technological development of indigenous firms in countries like Korea, Taiwan and 
China (Lall & Albaladejo, 2003). Adaptive innovation was not just limited to local 
firms in developing countries. Even foreign firms operating in these countries did 
mostly adaptive R&D. Lall (1995) argued that foreign firms’ R&D “that takes place 
in developing countries is limited, generally geared to specific adaptive tasks, and 
concentrated in the few countries with relatively advanced industrial sectors” (p. 120). 
Kim (1980) while tracing the evolution of Korean electronic industry, emphasized 
on the role of imports of foreign technologies and their diffusion/assimilation/
imitation in the domestic economy during 1960s−70s as the basis for indigenous 
technological development. Hobday (1995) highlighted the case of latecomer 
electronic firms from East Asia (South Korea, Taiwan, Hong Kong and Singapore) 
that began their technological activities around incremental improvements to acquired 
foreign technology and later shifted to creative innovation under the export-oriented 
policy regime. The nature of Indian R&D in the restrictive period of 1970s−1980s was 
also suggested to be more of adaptive in nature than creative (Desai, 1980; Katrak, 
1985). As the R&D in their initial period was mostly adaptive and incremental in a 
large number of developing or emerging economies, developing country firms are likely 
to have shortcomings in their product development capabilities. 
 Therefore, the localized technological change in developing regions mostly 
remained knowledge accumulation based on reverse engineering and development 
of cost-effective processes on the eve of the early 1990s. This technology gap of 
lacking adequate product development capabilities is due partly to their poor R&D 
infrastructure, weak linkages between business and R&D laboratories, small firm size 
and a smaller endowment of initial technical knowledge. It is clear that such technology 
gap and inadequacy in other strategic capabilities might turn out to be a powerful drive 
for firms from many developing countries, when faced with the policy of openness and 
increasing competition, to use M&As as seriously as improving their in-house R&D 
activities to overcome their limited product development capabilities.
A combination of market- and asset-seeking motivations appear to be driving 
recent M&As by developing country firms (Dunning & Lundan, 2008). Luo and Tung 
(2007) have explained how emerging market multinationals, given their competitive 
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weaknesses, are increasingly acquiring strategic assets from mature MNEs in developed 
countries to overcome their latecomer disadvantage in world markets. Forsans and 
Balasubramanyam (2010) suggested that access to technology and know-how is one of 
the main motives behind emerging firms’ foreign acquisition from India and China and 
argued that M&A is a more efficient and inexpensive source of technology than licensing 
agreements. Rasiah et al. (2010) contended that Indian, Chinese, and Brazilian firms 
are targeting US more and more for accessing both intellectual properties and markets. 
Rui and Yip (2008) suggested that Chinese firms are using overseas acquisitions, partly, 
for acquiring foreign strategic capabilities to offset their competitive disadvantages. 
Sauvant et al. (2010), Pradhan & Abraham (2005), Pradhan (2008a) and Pradhan & 
Singh (2009) emphasized the strategic asset-seeking motives of Indian acquiring firms, 
besides other firm-specific motivations. Buckley et al. (2007), Athreye & Kapur (2009), 
Rajan (2009), Pradhan (2010; 2011), and De Beule (2010) all have hypothesized about 
the important role of strategic asset-seeking motivation that drives acquisitions by 
Chinese and Indian MNEs, of course, in companionship with other crucial objectives 
like access to markets and natural resources. In the imbalance theory proposed by 
Moon & Roehl (2001) the rise of FDI by firms with weak competitive resources and 
from less developed countries is explained as an outcome of the imbalance between a 
firm’s existing resources and those it lacks.
The general model of technological change in developing countries, as presented 
above, has been applied to the case of Indian pharmaceutical industry in the following 
section. The basic idea is to appreciate the recent spell of overseas acquisitions by Indian 
pharmaceutical firms in the overall context of their existing technological strength and 
weakness.
 2.1. Localized Technological Change in Indian Pharmaceutical Industry
The post-Independence growth of Indian pharmaceutical industry and associated 
technological change can be broadly divided into four phases as shown in Table 1 
(Pradhan & Alakshendra, 2006). In the initial phase during 1947−1969, the industry 
was mostly dominated by foreign firms, which were primarily engaged in trading 
activities of formulations derived from imported bulk drugs (Chaudhuri, 1997; Kumar 
& Pradhan, 2003). Due to inadequate domestic capability, the Government intervened 
by starting public sector enterprises for local manufacturing of essential drugs. Towards 
the early 1970s, Indian pharmaceutical industry shifted to a new era of growth facilitated 
by adoption of a process patent regime and preferential policy treatment of domestic 
enterprises. The period 1970−1989 witnessed the emergence of a growing number of 
domestic firms occupying increasing share in domestic markets. As the Indian Patent 
Act 1970 only permitted a process patent for the pharmaceutical products and also for 
a short duration of just five years from the patent being granted, domestic firms were 
able to reverse engineer and develop alternative processes for patented drugs in other 
countries (UNCTAD, 2003). This has contributed to significant accumulation of 
domestic skills in cost effective process development and rapid growth of the industry 
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in the 1980s. Technological imitation, reverse engineering and cost-effective process 
development have come to be regarded as key competitive strategy of domestic firms 
(Aggarwal, 2007; Patibandla, 2006). Domestic enterprises based on large-scale reverse 
engineering and process innovation achieved near self-sufficiency in the technology and 
production of bulk drugs belonging to several major therapeutic groups and developed 
modern manufacturing facilities for all dosage forms like tablets, capsules, liquids, orals 
and injectibles.
TABLE 1.  growth stages of indian pharmaceutical industry since 1947
growth stages main features
I.
1947−1969
•	 MNEs	domination,	largely	import	dependent	and	minimal	export	activities.
•	 Insufficient	technological	base	for	local	production.
•	 Starting	of	public	sector	enterprises	for	local	drug	production.	
•	 Emphasis	 on	 general	 education	 and	 skill	 creation,	 infrastructure,	 institution	
building and planned development.
II.
1970−1989
•	 Enactment	of	the	Indian	Patent	Act	1970:	Creation	and	accumulation	of	firm-specific	
advantages by domestic firms under this new process patent regime. Imitation, 
incremental innovation and process development were the basic character of indigenous 
technological development in the pharmaceutical sector.
•	 Passing	of	different	regulations	like	FERA	and	New	Drug	Policy	1978	to	restrict	activities	
of MNEs in the sector. 
•	 These	policies	led	to	the	emergence	of	a	strong	domestic	sector	not	only	serving	domestic	
market but also interested in entering foreign markets through exports and greenfield 
outward investments. Trade deficits in pharmaceuticals were consistently reduced.
III. 
1990−1999
•	 Domestic	firms	now	dominate	the	pharmaceutical	 industry,	which	are	highly	export-
oriented contributing to rising trade surpluses.
•	 However,	the	openness	policy	and	impending	shift	to	product	patent	regime	under	the	
TRIPS and new regulatory requirement like GMP compliance started putting increasing 
pressures on Indian pharmaceutical companies.
•	 Indian	firms	started	improving	their	in-house	R&D	activities	with	greater	emphasis	on	
global manufacturing practices and novel delivery systems. 
•	 Apart	 from	 outward	 greenfield	 investments,	 Indian	 firms	 started	 exploring	 overseas	
acquisitions as another mode of internationalization.
•	 Pharmaceutical	 contract	manufacturing	and	 research	services	also	emerged	as	a	new	
growth strategy for the industry.
IV. 
2000−onwards
•	 The	 introduction	of	product	patent	 regime	 in	2005	sharply	 influenced	 technological	
strategies of capable Indian firms by increasing focus on product development. Growing 
sophistication	of	technological	capability	of	large	Indian	pharmaceutical	firms	is	reflected	
in tendency of out-licensing of drugs molecules to global firms.
•	 Rapid	growth	of	overseas	 acquisitions	 and	 increasing	 incidents	 of	 outsourcing	
including strategic alliances. 
•	 Partly,	overseas	acquisition	is	a	strategy	of	acquiring	new	technological	assets/
competencies. 
Source:	Adapted	from	Pradhan	&	Alakshendra	(2006)
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In the 1990s, Indian pharmaceutical industry continued with spectacular growth 
performance and impressive trade surpluses. The domestic firms out-competed 
foreign firms to be the dominant market player as a consequence of their stronger 
process development capabilities. For instance, in 1991 domestic firms accounted for 
about 70 and 80 per cent market shares in the case of bulk drugs and formulations 
respectively (Lanjouw, 1998). The industry turns out to be one of the most export-
oriented sectors in Indian manufacturing with more than 30 per cent of its production 
being exported to foreign markets (Pradhan, 2007). The economic openness policy 
of the home country and emerging regulatory requirements started forcing a number 
of Indian pharmaceutical firms to upgrade their manufacturing practices to the global 
level and expand their R&D focus to devise novel drug delivery systems (Smith, 2000; 
UNCTAD, 2003). Their main deficiencies of inadequate capabilities to develop new 
molecules, however, remain to be addressed seriously. The process patent regime has 
incentivized the process of technological change towards improvements in production 
process, raw material and intermediate inputs. However, Indian companies had little 
inducement to undertake research for product developments as other Indian companies 
can legally launch any new product by simply resorting to another new process. As a 
result, firm-level capability in product developments was significantly undermined. 
Also because the new product development involves costly and risky R&D strategy, 
very few domestic firms could think of pursuing such an innovation strategy (Smith, 
2000). 
The first decade of the twenty-first century saw profound changes in the technological 
strategies of Indian pharmaceutical firms. The re-entry of product patent regime 
on a global scale and strict quality norms in export markets have made Indian firms 
serious about improving their technological capabilities. The general trend among 
relatively large Indian pharmaceutical firms was to improve their R&D intensity with 
some pursuing the goal of developing new molecules. Yet some others decided in 
favour of joint R&D strategy with developed country firms or entering into contract 
manufacturing (Pradhan, 2006; Balcet & Bruschieri, 2010). It appears that some of 
Indian pharmaceutical firms are now trying to go beyond the process development 
based innovation strategy and to enlarge their product basket. For these firms, 
depending only on in-house R&D to broaden their product development capabilities 
is a too restrictive strategy. As they are too far behind their international competitors 
in terms of the size of product basket and scale of operation, inorganic path to product 
development capabilities can be as important as R&D. Both the in-house R&D and 
acquisition of foreign strategic assets can often complement each other, especially when 
firms possess weak product development capabilities. Therefore, it is not unrealistic to 
think that the recent overseas acquisitions by Indian pharmaceutical firms could be a 
result of their strategic competency building intention, in addition to the traditional 
objectives of accessing new market, efficiency-seeking and increasing global scale of 
operation.
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3. Acquisitions to mitigate technological inadequacies
As discussed above, strategic government interventions have succeeded in building 
local capability in the pharmaceutical sector but they have also created a number of 
limitations in pushing forward firm’s productivity and technological frontiers (Figure 1). 
While weaker intellectual property rights stimulated process innovation by Indian 
pharmaceutical companies in the past, in subsequent period of liberalization such a 
limited technological strategy emerged as an important obstacle to their growth and 
learning. It is also evident that Indian domestic pharmaceutical companies’ technological 
advantages remain confined to innovative cost-effective processes, discovery in novel 
drugs delivery system, self-reliance in producing quality raw materials and production 
led by quality management. However, these technological strengths are confined to a 
small group of large Indian pharmaceutical companies (Pradhan & Sahu, 2008).
Innovative Capabilities
Improvements in products/new products
Improvements in production process
Capability to produce quality raw  
material and intermediate inputs
Efficiency in Management  
and organization
Inadequate	capability:	 
Most serious innovation limit
High	capability:	 
Most important innovation advantage
High	capability:	 
Mostly self-reliant
Reasonably	good:	 
Not a major problem
Nature of Existing Technological Strength of 
Indian Pharmaceutical Firms
FIGURE 1.  A Simplistic Perspective on technological capabilities  
of indian Pharmaceutical firms
Source:	Own	construction.
When India opened up to the accelerating process of globalization and openness in the 
1990s, Indian pharmaceutical firms became aware of the diminishing advantages of their 
narrowly focused innovation strategies. The globalized market competition and product 
patent regime required Indian pharmaceutical firms to upgrade their innovation capa- 
bilities to include product development. When developing country firms with such 
inadequate competitive resources undertake overseas acquisitions, there is an increased 
possibility for them to seek merger and acquisitions (M&As) as a strategic tool to overcome 
their existing weakness in the knowledge base (Gupta & Ross, 2001). By helping to acquire 
innovative capabilities quickly, strategic acquisitions appear to have greater appeal to the 
latecomer firms over the alternative path of long term investments in in-house R&D with 
unpredicted results (Deng, 2007; Pradhan, 2008a). Such strategic asset-seeking OFDI 
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immediately upgrade acquiring firms to a higher scale of technological specialization 
and diversification and offer a way to overcome the entry barriers that exist in accessing 
developed countries markets. Added to these positive spinoffs, acquiring Indian firms are 
likely to derive immediate market expansion, economies of technological and business 
synergies, and to access new marketing skills, overseas sales distribution networks, and 
organizational knowledge (Figure 2). 
FIGURE 2.  Possible effects of overseas Acquisitions
Directly mitigate product development related  
deficiency in the innovation capabilities 
of Indian pharmaceutical firms
•	 Help	Indian	pharmaceutical	firms	to	enlarge	their	product	portfolio
•	 Provide	access	to	technologies	of	new	products	and	their	brandnames
•		 Benefits	from	tecnological	complementarities
OFDI for  
acquisition
•	 Access		to	manpowe	
with specialized mana-
gerial techological and  
marketing skills
•	 Access	to	
overseas sales 
and distribu-
tion networks
•	 Access	to	 
existing  
overseas  
customer base
•	 Potential	benefits	from	
knowledge spillovers 
in innovative  
developed countries
New  
products
New  
skills
Marketing 
networks
Existing 
market
Knowledge 
spillovers
Source:	Own	construction.
In view of the multiplicity of benefits that M&As bring with them, it is not surprising 
that an increasing number of Indian pharmaceutical companies have begun to acquire 
foreign companies and assets since the last decade. It seems some of these firms are now 
trying to go beyond their process development based innovation strategy and to enlarge 
their product baskets via inorganic route of acquisition. A number of studies (Smith, 
2000; Pradhan & Abraham, 2005; Pradhan & Alakshendra, 2006; Rajan, 2009; Gubbi 
et al., 2010) tend to indicate the strategic considerations behind overseas acquisitions of 
Indian pharmaceutical companies. Pradhan (2008b) provided brief cases of five largest 
acquirers from Indian pharmaceutical sector where managerial comments on different 
overseas acquisitions corroborate that these acquirers are using acquisition as a critical 
strategy for improving their existing technological competencies and also as a means of 
accessing new markets and facilitating exports from home country.
One of the crucial indications in this process of strategic assets-seeking investments 
by Indian pharmaceutical firms is the spatial distribution of such investments. In order 
to acquire superior and strategic technological assets including a broadened range of 
products, Indian acquirers are expected to disproportionately turn to developed countries 
rather than developing economies. Developed markets are centres of global technological 
developments and skills. Therefore, if acquiring Indian pharmaceutical firms are motivated 
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to acquire advance technologies, then they are likely to concentrate more on picking up 
assets in these developed markets. In addition, it would be appropriate to say that the choice 
of Indian pharmaceutical firms selecting developed locations over developing regions may 
also	reflect	their	desire	to	enhance	their	geographical	market	focus	hitherto	dominated	by	
developing countries through exports from home and overseas production. 
Tables 2 and 3 summarize correspondingly the trends and geographical patterns of 
overseas acquisitions by Indian pharmaceutical MNEs in the last decade. It can be seen 
that overseas acquisitions by Indian pharmaceutical firms is a recent phenomenon that 
is gaining a substantial dimension in terms of value and number of acquiring Indian 
companies. As many as 52 Indian pharmaceutical companies have undertaken a total of 
139 foreign acquisitions valued over US$3.4 billion during 2000–2009 (Table 2). The 
number of host countries to such acquisition is increasing as well, totaling 33 at the end 
of June 2009. In terms of geographical focus, Indian pharmaceutical acquisitions spread 
across a total of 21 developed countries, 11 developing countries and one transition 
economy (Table 3). Developed region with 92.6 per cent share in total acquisition value 
is clearly the leading host location for these acquisition activities. Such concentration 
of Indian pharmaceutical acquisitions in developed regions is indicative of the trend 
that Indian pharmaceutical firms might be using acquisition as a strategy to overcome 
their prominent technological shortfall, namely inadequate product development 
capabilities. Skill-intensive and R&D-oriented developed countries are thus emerging 
as attractive destinations for Indian firms seeking new products and new markets. 
TABLE 2.  foreign Acquisitions by indian Pharmaceutical firms, 2000–09
year
Acquisition in uSd million in number
value Acquisition deals
Acquiring indian 
firms
target 
countries
2000 -- 2 2 2
2001 -- 1 1 1
2002 13 6 3 5
2003 114 6 6 4
2004 68 10 8 8
2005 473 28 16 16
2006 1359 28 20 13
2007 773 19 15 13
2008 585 36 24 14
2009 4 3 3 3
All Years 3389 139 52 33
Note:	data	for	2009	are	through	June;	for	all	years,	the	number	of	target	countries	and	acquiring	Indian	firms	
is obtained by single counting of a country and a firm respectively during 2000–09; -- deals values were not 
disclosed. 
Source: Based on dataset constructed from different reports from newspapers, magazines, and financial consulting 
firms including Hindu Business Line, Economic Times, Financial Express, Business World, Grant Thornton India, 
and ISI Emerging Market.
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TABLE 3.  regional Pattern of foreign Acquisitions by indian Pharmaceutical firms, 2000–09
region/country Acquisition in uSd million
in number
Acquisition deals Acquiring indian firms
developing economies 231 (6.8) 24 (17.3) 14
 Africa 95 (2.8) 5 (3.6) 5
Tanzania 0 (0.0) 1 (0.7) 1
South Africa 95 (2.8) 4 (2.9) 4
Latin America and Caribbean 96 (2.8) 9 (6.5) 4
Mexico 59 (1.7) 2 (1.4) 2
Argentina (0.0) 1 (0.7) 1
Brazil 36 (1.1) 5 (3.6) 3
Venezuela 1 (0.0) 1 (0.7) 1
 Asia 40 (1.2) 10 (7.2) 8
China 6 (0.2) 6 (4.3) 4
Philippines (0.0) 1 (0.7) 1
Singapore 14 (0.4) 1 (0.7) 1
Thailand (0.0) 1 (0.7) 1
UAE 20 (0.6) 1 (0.7) 1
 economies in transition 20 (0.6) 1 (0.7) 2
Russia 20 (0.6) 1 (0.7) 1
 developed economies 3138 (92.6) 114 (82.0) 48
 America 758 (22.4) 43 (30.9) 27
Canada 256 (7.6) 3 (2.2) 2
USA 502 (14.8) 40 (28.8) 27
 Asia 457 (13.5) 5 (3.6) 4
Israel 454 (13.4) 2 (1.4) 1
Japan 3 (0.1) 3 (2.2) 3
 Europe 1848 (54.5) 60 (43.2) 32
Belgium 279 (8.2) 3 (2.2) 3
Bulgaria 7 (0.2) 1 (0.7) 1
Czech Republic (0.0) 1 (0.7) 1
Denmark 6 (0.2) 1 (0.7) 1
France 86 (2.5) 3 (2.2) 3
Germany 664 (19.6) 10 (7.2) 9
Hungary (0.0) 2 (1.4) 2
Ireland 150 (4.4) 2 (1.4) 2
Italy 2 (0.1) 6 (4.3) 5
Norway (0.0) 1 (0.7) 1
Poland 8 (0.2) 3 (2.2) 3
Romania 321 (9.5) 1 (0.7) 1
Spain 66 (1.9) 5 (3.6) 4
Sweden (0.0) 1 (0.7) 1
Switzerland 77 (2.3) 3 (2.2) 2
UK 182 (5.4) 17 (12.2) 13
 oceania 75 (2.2) 6 (4.3) 5
Australia 75 (2.2) 6 (4.3) 5
grand total 3389 (100) 139 (100) 52
Note:	Percentage	shares	are	in	parentheses;	Data	for	2009	are	through	June.
Source: Same as Table 2.
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4. locational Approach to model firms’ motivations  
of foreign Acquisitions 
A number of recent studies have adopted the analysis of locational choice to incorporate 
diversities of FDI motivations characterizing the rise of emerging market MNEs (e.g. 
Buckley et al., 2007; Cheung & Qian, 2008; Kolstad & Wiig, 2009; Pradhan, 2010, 
2011; Pradhan & Singh, 2010; De Beule, 2010). The locational choice model has 
allowed these studies to integrate different possible motivations of emerging firms 
as to why they seek certain host countries for situating their outward investments 
more than other potential host economies. The present study shall largely follow this 
locational approach with an eye to gain some insights into Indian pharmaceutical firms’ 
motivations behind overseas acquisitions.
Behrman (1972), Dunning (2000) and UNCTAD (2006) have classified FDI 
projects into four types by motivations. These are firm-specific motives to seek resources, 
markets, efficiency and created/strategic assets. Firms pursue FDI driven by any one or 
combination of these motives and tend to choose locations that integrate these motives 
effectively with greater favourable resources and institutional endowments. UNCTAD 
(1998) listed several locational factors for MNE motivations as set out in Table 4 and 
hypothesized that “host countries that offer what TNCs are seeking, and/or host 
countries whose policies are most conducive to TNC activities, stand a good chance of 
attracting FDI” (p. 91). After reviewing the literature and analysis from various global 
surveys on FDI motivations, UNCTAD (2006) indicated that Chinese FDI, and Indian 
FDI to some extent, is taking place with the incentive of securing existing markets in 
developed countries with the parallel objective of acquiring strategic assets to improve 
firm-specific competitiveness. Especially, Indian MNEs’ overseas expansion is mostly 
for mixed reasons where their FDI is simultaneously for market-seeking and created 
asset-seeking. For a sample of Indian pharmaceutical firms operating in Brazil, Sweet 
(2010) found market-seeking activities to be their dominant motivation.
The link between acquiring firms’ motivations and location can theoretically be 
derived from the general theory of industrial location, gravity model of international 
trade and economic theory of foreign investment. In the location theory (Laundhardt, 
1885; Weber, 1929; Hotelling, 1929), firms’ industrial location decision is expected 
to depend on differences in inputs and transportation cost and size of demand at 
alternative locations. Accordingly, one can see the need for Indian pharmaceutical 
firms to access critical productive inputs like new technology, skills, and marketing 
knowledge and to supply to a large size host market as a basis for the specific spatial 
pattern of their foreign acquisitions. By resorting to the gravity framework (Linnemann, 
1966;	Deardorff,	1984)	of	bilateral	trade	flows,	several	studies	have	hypothesized	FDI	
flows	 to	be	positively	affected	by	 incomes	of	host	 and	 the	 source	country	and	 to	be	
discouraged by the distance between them (e.g. Hufbauer et al., 1994; Bevan & Estrin, 
2004; Bénassy-Quéré et al., 2007). These postulations can be relevant for foreign M&As 
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by national firms as well. In the eclectic theory of FDI (Dunning, 1988, 1998) host 
countries possessing higher endowment of locational advantages like large markets, 
high growth, investment friendly policies, adequate infrastructure, etc. are likely to be 
more	favourable	host	to	global	FDI	flows.
TABLE 4.  mne motivation and location choice
fdi projects by 
mne motivations main economic determinants in host countries
A.
Market-seeking
•	 Market size and per capita income
•	 Market growth
•	 Access to regional and global markets
•	 Country-specific consumer preferences
•	 Structure of markets
B.
Resource-seeking
•	 Availability of natural resources (natural gas, oils, minerals)
•	 Endowment of cheap unskilled labour
•	 Presence of adequate skilled labour force
• Level and quality of physical infrastructure (ports, roads, power, 
telecommunication)
C.
Efficiency-seeking
•	 Lower cost of resources and intermediate inputs, adjusted for productivity 
of labour resources
• Membership of a regional integration agreement conducive to the 
establishment of regional corporate networks
D.
Strategic  
asset-seeking
• Technological and other created assets (e.g. brand names), including as 
embodied in individuals, firms and clusters.
Source:	Adapted	from	UNCTAD	(1998)
4.1. Empirical specification of the location model
In the backdrop of above theoretical literature and earlier empirical studies on 
locational choice of emerging multinationals (Buckley et al., 2007; Cheung & Qian, 
2008; Kolstad & Wiig, 2009; Pradhan, 2010; Pradhan & Singh, 2010; De Beule, 2010), 
the present study has specified the cross-country distribution of foreign acquisitions 
by Indian pharmaceutical firms as a function of a set of host country-specific factors. 
Gross domestic product (GDP), growth of GDP (GDPG) and per capita GDP (PGDP) 
are three host market related variables considered in the empirical specification and are 
expected to attract more acquisitions by Indian pharmaceutical firms if acquisitions are 
a strategy for these firms to access new markets. Acquisitions can also be undertaken 
to facilitate exports to the host market, therefore, host pharmaceutical purchase 
(IMP) from the home country is another possible factor considered in the empirical 
specification. Host countries with greater technological resources, proxied by the 
number of residents’ applications filings for patent (PAT) and trade mark (TRD) and 
higher	skill	as	reflected	by	school	enrolment	(ENRL), are postulated to be in a better 
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position to attract acquisitions by strategic resource-seeking Indian pharmaceutical 
firms. 
The host country policy regime towards FDI measured as inward FDI stock as a 
per cent of GDP (Zhou & Lall, 2005) is included in the estimation as other important 
locational factors attracting Indian pharmaceutical acquisitions. The remoteness of a 
host country from India might play a discouraging role as it tends to increase the cost of 
foreignness and management of business at a distance (Leamer & Storper, 2001) for 
acquiring pharmaceutical companies. The cultural proximity measured by the existence 
of a common language (LAN) between a host country and India is likely to act as a 
positive pull factor by reducing transaction costs and hesitation on the part of acquiring 
Indian pharmaceutical firms. 
Therefore, the estimated empirical model in this study can be formulated as 
follows:
ACQiT =  α + β1GDPit + β2GDPGit + β3PGDPit + β4PATit+ β5 TRDit 
 + β6 ENRLit + β7 IMPit   + β8 FDISit  + β9 DISTi  + β10 LANi  + ui (A)
Where,
ACQiT  = Number of acquisitions made by Indian pharmaceutical companies in ith host 
country during the period T (2002–2008);
GDPit  = Natural log of GDP (constant 2000 USD) of ith host country in the year 2002;
GDPGit  = Annual percentage change in GDP (constant 2000 USD) of ith host country in 
the year 2002;
PGDPit  = Natural log of per capita GDP (constant 2000 USD) of ith host country in the 
year 2002;
PATit  = Natural log of resident patent applications per $ billions of current GDP of ith 
host country in the year 2002;
TRDit  = Natural log of resident trade mark applications per $ billions of current GDP of 
ith host country in the year 2002;
ENRLit  = Natural log of gross secondary school enrolment (per cent) of ith host country in 
the year 2002;
IMPit  = Natural log of ith host country’s pharmaceutical imports from India as percentage 
of its total pharmaceutical imports in the year 2002 (1 has been added to the series 
before taking logs to take account of countries with zero pharmaceutical imports 
from India);
FDISit  = Natural log of inward FDI stock as percentage of GDP of ith host country in the 
year 2002;
DISTi  = Natural log of distance in kilometres between India and ith host country.
LANi  = Takes value of one if a common language is spoken by at least 9% of the 
population of both ith host country and India, zero otherwise;
ui  = Random errors.
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As can be seen from the above empirical setting, our approach has been to see if the initial 
locational conditions/factors can explain the observed locational pattern of cummulative 
foreign acquisitions made by Indian pharmaceutical firms in the subsequent period. This 
method appears to be more appropriate than estimating Equation A for the panel of 
year-wise cross country distribution of overseas acquistions as the latter is characterized 
by excessive zeros given that yearly acquistions are confined to just a few countries. For 
example for the single year 2002 there are just five countries receiving Indian pharmaceutical 
acquistions out of an estimable sample of 58 host countries.
4.2. Data source, method of estimation and results 
The empirical application of Model A has been conducted with the help of data collected 
from a number of sources. The information on the dependent variable, namely the total 
number of Indian pharmaceuticals acquisitions by host countries during 2002−2008 
is obtained from an in-house dataset constructed from M&A reports in newspapers and 
magazines like the Hindu Business Line, the Economic Times, the Financial Express and 
the Business World with supplementary information from consulting firms like Grant 
Thornton India and ISI Emerging Market. The World Development Indicators (WDI) 
2009 has been the basic source for host country data on GDP, GDP growth rate, 
real per capita GDP and secondary school enrolment ratio. Host country imports of 
pharmaceuticals from the world and India have been drawn from the United Nations 
Commodity	 Trade	 Statistics	 Database	 (COMTRADE).	 Resident	 patent	 filings	 and	
applications for trade mark were obtained from the online patent statistics of the World 
Intellectual Property Organization (WIPO). The information on the inward FDI stock 
as percentage of GDP is drawn from the online database of the UNCTAD. The CEPII 
Distance database, 2006 is the primary source for data related to the existence of a 
common ethnic language between India and host countries and also on geographical 
distances (in kilometers) between them. 
Estimation results and inference
For those models having non-negative counts as the dependent variable, one can use 
the Poisson maximum likelihood estimation to get consistent coefficient estimates 
if the dependent variable is equi-dispersed (i.e. the conditional variance equals the 
conditional mean) and does not possess excessive number of zeros (Cameron & 
Trivedi 1998; Hilbe, 2007). However, if the Poisson distribution is over-dispersed 
and extremely censored like ours where the sample variance is 15 times the mean and 
the 75th percentile value of the distribution is zero as shown in appendix Table 1, the 
standard Poisson estimator is no longer consistent. Hardin and Hilbe’s (2007) censored 
Poisson method with robust standard errors is an appropriate method that has capacity 
to account for extra variability and excess zeros in the count data. The present study, 
therefore, has adopted the censored Poisson method to estimate the coefficients of 
Model A. Hilbe’s (2005) STATA programme, namely cpoisson has been used to obtain 
the empirical results presented below in this paper. 
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A preliminary diagnostic check like the computation of the simple correlation matrix 
suggests that the sample suffers from higher degree of collinearity (appendix Table 2). 
PGDP is not only significantly correlated with GDP but also with TRD, ERNL, and 
IMP. A strong correlation can also be seen between ENRL and IMP. In view of this, 
the modified Gram-Schmidt procedure (Golub & Van Loan, 1996) has been used to 
generate orthogonalized versions of explanatory variables by assuming market-related 
variables to be most important in the order, followed by strategic asset related indicators 
and then other host factors. In this procedure, orthogonalized variables are created by 
removing the effects of all the preceding factors (Sribney, 1998). 
Table 5 summarizes the results obtained from the censored Poisson estimation of 
the host country determinants of Indian pharmaceutical acquisitions. There are three 
sets of results under regressions 1, 2 and 3 respectively related to separate estimations 
done by considering host country market related factors only, both market and strategic 
asset characteristics, and all the factors as specified in Model A. 
Among the three host market related factors included in regression 1, GDP comes 
up with statistically significant coefficient with predicted positive sign. GDPG and 
PGDP both emerge with effects that are statistically not different from zero. Therefore, 
the initial absolute size of the host market appears to be the most attractive demand 
factor for acquisitions by Indian pharmaceutical MNEs. This tends to confirm the 
survey results of the UNCTAD (2006) that found market-seeking motivation as being 
foremost for a sample of outward investing Indian firms. However, Indian acquirers in 
the pharmaceutical sector seem to be less concerned with the initial level of per capita 
income of the host country. Given the relatively low income elasticity of demand 
for medicines, most Indian pharmaceutical MNEs are limiting their market-seeking 
objectives to the absolute size of the host market.
In regression 2, strategic asset characteristics of host countries are included along 
with their market features. Now the GDP, PAT and ENRL all turn up with positive 
coefficients and are statistically significant. It would indicate that Indian firms from the 
pharmaceutical sector are focusing their acquisitions on a combination of accessing 
host market (GDP) and strategic resource base (PAT and ENRL). These companies 
are found to be attracted by both the intensity of patent activity and general skill in host 
countries. As Indian acquiring firms possess a narrow range of product development 
profile, acquiring foreign companies in patent-intensive host countries may be serving 
a strategic goal. This would reinforce our prediction that overseas acquisitions of Indian 
pharmaceutical companies are partly driven by a rational vision of a technological 
upgrade. 
The expansion of the estimation to include other possible factors in regression 
3 further corroborates the robustness of the role of market-seeking and strategic 
resource-seeking motivations behind the spatial distribution of Indian pharmaceutical 
acquisitions. The host market size, resident patent intensity and the degree of skill 
continue to be important locational factors with significant positive effects. Among 
the additional variables, IMP comes up with a negative sign but is not significant. This 
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suggests that Indian pharmaceutical acquisitions were directed not necessarily to the 
host countries that were purchasing more pharmaceuticals from India. The negative 
coefficient of IMP is understandable because Indian pharmaceutical firms concentrated 
their acquisitions more in developed countries while developing countries are the major 
traditional export markets for Indian pharmaceuticals.
TABLE 5.  censored Poisson estimation of locational determinants of indian Pharmaceutical 
Acquisitions
Dependent variable: number of Indian pharmaceutical acquisitions
independent variables
regression 1
(host market 
factors only)
regression 2
(host market and 
strategic asset factors)
regression 3
(host market, 
strategic asset, policy 
and other factors)
GDP 2.906110***(11.49)
2.627682***
(5.00)
3.584235***
(3.60)
GDPG -0.317024(1.01)
-0.144057
(0.47)
-0.164420
(0.48)
PGDP 0.095717(0.45)
0.048937
(0.21)
-0.014913
(0.05)
PAT 0.703258**(2.51)
0.736097**
(2.35)
TRD -0.419338(1.19)
-0.823366
(1.30)
ENRL 0.779575***(2.90)
0.890256***
(3.58)
IMP -0.564703(0.93)
FDIS 1.772007**(2.39)
DIST -0.364328(1.14)
LAN 0.334016(1.21)
Constant -3.210670***(7.54)
-1.237946***
(2.76)
-1.553595***
(3.01)
Wald chi2 133.67 41.63 58.04
Prob > chi2 0.0000 0.0000 0.0000
Log pseudo-likelihood -59.233554 -26.764917 -15.446522
No. of host countries 184 62 58
Note:	 Robust	 z-statistics	 in	 parentheses;	 *	 significant	 at	 10%;	 **	 significant	 at	 5%;	 ***	 significant	 at	 1%;	 all	
explanatory variables are in orthogonalized form.    
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The policy variable FDIS is significant with a positive sign. It would imply that host 
country policy regime is an important factor in defining the cross-country distribution 
of Indian pharmaceutical acquisitions. Indian pharmaceutical firms are likely to locate 
more of their acquisition projects in host countries with liberal policy towards foreign 
investment. DIST has a negative sign but is not significant. Indian pharmaceutical 
acquisitions, therefore, are not bounded by physical distance. LAN comes up with a 
positive coefficient but fails to achieve accepted level of significance. It would appear 
that Indian pharmaceutical acquisitions are taking place due to other considerations 
than the geographical and cultural proximities with India.
5. Summary and concluding remarks
This paper has examined the foreign acquisition activities of Indian pharmaceutical 
MNEs both in the general framework of localized technological change in emerging 
economies and a parsimonious empirical model of FDI location. The transition of a 
number of emerging economies from a phase of adaptive R&D based on imported 
technologies in the past to the accumulation of indigenous innovative capabilities in 
the 1980s has its limitations as much of these innovative activities centered more on 
process developments than expanding product development capabilities. The adoption 
of competitive openness policies in the 1990s by many emerging economies brought 
about a sharp growth in overseas acquisitions by their national firms. Such foreign 
acquisitions by emerging economies firms with weak product development capabilities 
are likely to be for accessing new products, technologies, brands and skills needed for 
facing immediate market competition, besides accessing new markets. 
The changing profile of growth and technological capabilities in Indian pharma-
ceutical industry largely highlights the similar propositions obtained from the literature 
of technological change in emerging economies. Despite the initial constraints of being 
a developing country and non-existent productive base in the modern pharmaceutical 
sector, India could build a very competitive pharmaceutical industry. The strategic 
government policies including public sector drug production, adoption of short duration 
process patent regime and strong monitoring of activities of foreign companies, resulted 
in significant growth of domestic investment in the pharmaceutical sector and increased 
local technological activities mainly in the form of cost-effective process development. 
This led to a rise of domestic productive capacity to satisfy growing demand for drugs 
and prompted a consistent export surge to overseas markets.
It is in the 1990s that the issue of a broad-based innovation strategy for long run 
growth of Indian pharmaceutical firms started attracting corporate and expert attention. 
The liberalization measures and a product patent regime made it imperative for Indian 
pharmaceutical firms to enlarge their innovation strategy towards product-oriented 
R&D. Many large Indian pharmaceutical companies realized these challenges and went 
for suitable measures like putting more resources in product and process development. 
In addition, some of these firms have also opted for overseas acquisition as a conscious 
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corporate strategy since the last decade. It is believed that the recent boom in overseas 
acquisitions by these firms partially represents their strategic motivation for acquiring 
new products, skills and technologies to overcome their existing inadequate product 
development capabilities. The concentration of Indian pharmaceutical acquisitions 
in innovation-driven developed countries tends to corroborate the above strategic 
postulation.
The empirical results from the locational analysis based on the censored Poisson 
regression have generally tended to further validate the role of strategic resource-seeking 
motivations behind foreign acquisitions of Indian pharmaceutical MNEs. The foreign 
acquisitions of these firms have been found to be more attracted to host countries 
that offer a large domestic market, strong patenting activities, skilled human resource 
base and that pursue a liberal foreign investment regime. Strategic asset-bases of host 
countries like the residents’ patents and skills are, thus, appear to be increasingly driving 
the geographical pattern of foreign acquisitions of Indian pharmaceutical firms holding 
the domestic market size (GDP) and policy regime constant. As Indian pharmaceutical 
firms had inadequate product development capabilities on the eve of the openness 
policies in the early 1990s, their acquisitions in patent- and skill-intensive countries 
is likely to be a strategy to improve their competitive advantages by accessing new 
technologies and products. In this sense overseas acquisition can be seen as a means of 
overcoming limited product development capabilities that characterize the majority of 
Indian pharmaceutical companies. Overall, these results support the UNCTAD (2006) 
observation that Indian FDI is mostly for a mixed purpose of accessing new markets 
and created assets.
 Although overseas acquisition can be important for enhancing firm-specific 
technological capabilities and for entering into new markets, they are also challenging 
for acquiring Indian pharmaceutical firms in a number of ways. Investment requirements 
in acquisition are quite substantial and not all Indian pharmaceutical firms have access 
to such resources. Especially, small- and medium-sized pharmaceutical units that 
dominate the Indian pharmaceutical industry shall not be able to benefit from the 
acquisition strategy. They do not have financial, technological and skill resources to 
undertake overseas acquisition to improve their product portfolio. Therefore, the scope 
and opportunities that are associated with acquisition strategy are limited to relatively 
large Indian pharmaceutical companies.
Since Indian pharmaceutical companies are new to global production, overseas 
acquisition involves significant market and operational risks. In the preparatory stage, 
the challenge is to decide on target markets and to identify target companies that can fit 
well into the requirements of Indian acquiring companies. In addition, Indian firms are 
required to determine the transaction value, negotiate with potential target companies 
and obtain information related to host country legal and environment clearances. 
Although financial accounting and consultancy firms help in these efforts, Indian 
firms should have adequate in-house skills to manage these issues more realistically. 
Insufficient knowledge of host country laws, regulatory delays, strong legal monitoring 
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in host developed countries related to manufacturing process, and quality of drugs and 
unexpected changes therein, rapid changes in demand and prices, growing competition, 
etc., represent high risk entailed in overseas acquisition. 
After acquisition, an Indian firm faces operational challenge to carry forward 
acquired production activities in foreign countries. The immediate issue is the post-
acquisition integration that addresses the theme of harmonizing different work cultures, 
managerial practices, employment policies, etc., successful integration of the acquired 
overseas units and putting them to efficient production. The scope for absorbing newly 
acquired foreign knowledge and benefiting from scale expansion clearly depends on the 
technological capabilities of acquirers themselves.
It is clear that without a well designed acquisition strategy, acquiring Indian 
pharmaceutical companies may not realize intended benefits from such activities. As 
long as Indian acquiring firms are aware of the potential risks involved in acquisition and 
well prepared to face such eventualities, overseas acquisitions can contribute to their 
greater geographical and economic diversification and upgrading of their technological 
capabilities significantly.
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Appendix
TABLE 1.  Summary of the dependent variable
number of indian pharmaceutical acquisitions by host countries
Percentiles No. Std. Dev. 3.294206
75% 0 Mean 0.719577
90% 2 Variance 10.8518
95% 3 Obs. 189
99% 17
Note: Calculation is based on total number of host countries.
TABLE 2.  correlation matrix
GDP GDPG PGDP PAT TRD ENRL IMP FDIS DIST LAN
GDP 1.0000
GDPG -0.1573 1.0000
PGDP 0.5537 -0.3551 1.0000
PAT 0.0975 0.1754 0.1406 1.0000
TRD -0.3820 0.3010 -0.5791 0.0939 1.0000
ENRL 0.2522 -0.1918 0.7075 0.4880 -0.2004 1.0000
IMP -0.3307 0.1992 -0.6719 -0.2358 0.3781 -0.5666 1.0000
FDIS -0.1974 0.1960 0.2069 -0.1203 -0.1476 0.1592 -0.0879 1.0000
DIST 0.2061 -0.3169 0.4216 -0.3832 -0.0563 0.2457 -0.2101 0.2464 1.0000
LAN 0.1260 -0.0117 0.2825 -0.0978 -0.2847 0.0978 0.0062 0.3240 0.1874 1.0000
Note:	obs=58.
